Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
Haitao ChenRong NaVignesh T PackiamCarly A ConranDeke JiangSha TaoHongjie YuXiaoling LinWei MengS Lilly ZhengCharles B BrendlerBrian T HelfandJianfeng XuPublished in: The Prostate (2017)
Risk assessment using currently available SNPs is justified. Multiple GRS values from evolving sets of SNPs provide a valuable tool for better refining risk.